| Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new … L Else, V Watson, J Tjia, A Hughes, M Siccardi, S Khoo, D Back Journal of Chromatography B 878 (19), 1455-1465, 2010 | 162 | 2010 |
| Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy A Yilmaz, C Verhofstede, A D'avolio, V Watson, L Hagberg, D Fuchs, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (5), 590-596, 2010 | 85 | 2010 |
| Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients A Yilmaz, V Watson, L Else, M Gisslèn Aids 23 (18), 2537-2540, 2009 | 67 | 2009 |
| Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention A Jackson, G Moyle, V Watson, J Tjia, A Ammara, D Back, M Mohabeer, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (3), 275-281, 2013 | 63 | 2013 |
| Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia S Nightingale, AM Geretti, A Beloukas, M Fisher, A Winston, L Else, ... Journal of neurovirology 22, 852-860, 2016 | 59 | 2016 |
| Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study LJ Else, A Jackson, R Puls, A Hill, P Fahey, E Lin, A Amara, M Siccardi, ... Antimicrobial agents and chemotherapy 56 (3), 1427-1433, 2012 | 46 | 2012 |
| Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy B Mora-Peris, V Watson, JH Vera, R Weston, AD Waldman, S Kaye, ... Journal of Antimicrobial Chemotherapy 69 (6), 1642-1647, 2014 | 38 | 2014 |
| Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals A Jackson, V Watson, D Back, S Khoo, N Liptrott, D Egan, K Gedela, ... Journal of acquired immune deficiency syndromes (1999) 58 (5), 450, 2011 | 35 | 2011 |
| CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study L Garvey, M Nelson, N Latch, OW Erlwein, JM Allsop, A Mitchell, S Kaye, ... Journal of antimicrobial chemotherapy 67 (1), 206-212, 2012 | 34 | 2012 |
| Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers M Boffito, A Jackson, M Lamorde, D Back, V Watson, J Taylor, L Waters, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 52 (2), 222-227, 2009 | 34 | 2009 |
| Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval A Yilmaz, V Watson, L Dickinson, D Back Antimicrobial agents and chemotherapy 56 (9), 4583-4585, 2012 | 33 | 2012 |
| Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients J Moltó, M Valle, D Back, S Cedeno, V Watson, N Liptrott, D Egan, ... Antimicrobial agents and chemotherapy 55 (1), 72-75, 2011 | 32 | 2011 |
| Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study JR Santos, JA Muñoz-Moreno, J Moltó, A Prats, A Curran, P Domingo, ... PLoS One 8 (7), e70201, 2013 | 31 | 2013 |
| Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans K Wakeham, R Parkes-Ratanshi, V Watson, AB Ggayi, S Khoo, DG Lalloo Journal of antimicrobial chemotherapy 65 (2), 316-319, 2010 | 29 | 2010 |
| Re‐reading of OraQuick HIV‐1/2 rapid antibody test results: quality assurance implications for HIV self‐testing programmes V Watson, RJ Dacombe, C Williams, T Edwards, ER Adams, CC Johnson, ... Journal of the International AIDS Society 22, e25234, 2019 | 14 | 2019 |
| Usability and acceptability of oral-based HCV self-testing among key populations: a mixed-methods evaluation in Tbilisi, Georgia E Fajardo, V Watson, M Kumwenda, D Usharidze, S Gogochashvili, ... BMC Infectious Diseases 22 (1), 1-14, 2022 | 9 | 2022 |
| Regulation of HIV self‐testing in Malawi, Zambia and Zimbabwe: a qualitative study with key stakeholders RJ Dacombe, V Watson, L Nyirenda, C Madanhire, M Simwinga, ... Journal of the International AIDS Society 22, e25229, 2019 | 8 | 2019 |
| Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers A Jackson, A D'avolio, V Watson, S Bonora, D Back, J Taylor, K Armenis, ... Journal of antimicrobial chemotherapy 66 (4), 885-889, 2011 | 7 | 2011 |
| Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients L Dickinson, AGA Jackson, LJ Garvey, V Watson, SH Khoo, A Winston, ... Journal of the International AIDS Society 13, 1-1, 2010 | 5 | 2010 |
| Population pharmacokinetic modelling of plasma and intracellular once daily ritonavir-boosted darunavir in HIV-infected patients L Dickinson, A Jackson, L Garvey, V Watson, S Khoo, A Winston, M Boffito, ... Twelvth International Workshop on Clinical Pharmacology of HIV Therapy, 13-15, 2011 | 4 | 2011 |
